Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 10Breast Neoplasms 8Colorectal Neoplasms 7Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Melanoma 4COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Resectable Localized Prostate Cancer 1Refractory or Relapsed Solid Tumors 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × Hydroxychloroquine × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡